SCHEMBL2458963

SCHEMBL2458963

N#Cc1cccc(-c2ccc(=O)n(Cc3cccc(-c4ncc(O[C@@H]5CN[C@H](C(=O)O)C5)cn4)c3)n2)c1

nearest known ligand 0.61

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 18/20 0.61
▸ NQO2 P16083 1/20 0.61
▸ IRAK1 P51617 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2531389 0.92 MET (0.61) METNQO2IRAK1
SCHEMBL2489119 0.87 MET (0.60) METNQO2IRAK1
SCHEMBL3092215 0.85 MET (0.71) METNQO2
SCHEMBL2531395 0.85 MET (0.64) METNQO2
SCHEMBL2530903 0.84 MET (0.67) METNQO2
SCHEMBL3090821 0.82 MET (0.83) METNQO2
SCHEMBL2530202 0.81 MET (0.61) METNQO2
SCHEMBL3091906 0.80 MET (0.80) METNQO2
SCHEMBL2458198 0.79 MET (0.77) METNQO2
SCHEMBL3084098 0.79 MET (0.62) METNQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257181-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-10-20 — — US claimed
EP-2367815-A1 PYRIDAZINONE DERIVATIVES Merck Patent GmbH (DE) 2011-09-28 — — EP claimed
WO-2010072296-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2010-07-01 — — WO claimed
EP-2367815-B1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2015-01-14 — — EP disclosed
EP-2367815-B1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2015-01-14 — — EP disclosed
US-8637518-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-01-28 — — US disclosed
US-8637518-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-01-28 — — US disclosed
US-8637518-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-01-28 — — US disclosed
US-20110257181-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-10-20 — — US disclosed
US-20110257181-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-10-20 — — US disclosed
US-20110257181-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-10-20 — — US disclosed
EP-2367815-A1 PYRIDAZINONE DERIVATIVES Merck Patent GmbH (DE) 2011-09-28 — — EP disclosed
WO-2010072296-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2010-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257181-A1 PYRIDAZINONE DERIVATIVES MET, TYRO3, ERBB2 MET 1/4885NQO2 600/4885IRAK1 427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback